2019 was an exciting year for Pharmacelera and we look forward to 2020 with energy and commitment. Stay tuned for updates in
By Javier Vazquez – Dec. 11, 2019 Virtual Screening (VS) is a core in-silico technology in medicinal and computational chemistry. Several tools
Researchers at Bellvitge Biomedical Research Institute will develop a research project with the company Pharmacelera to look for new molecules that block
PharmScreen evolves day by day thanks to the feedback of many computational and medicinal chemists! We have been incorporating different features to
Why protein-protein interactions are important? Protein-protein interactions (PPI) play a major role in several of the cellular functions and processes that take
Today, the amount of data generated in many fields such as engineering, social sciences or medicine is suffering a tremendous scale-up. Extraction
CCDC and Pharmacelera combine virtual screening and machine learning expertise to help scientists accelerate drug discovery Barcelona and Cambridge, UK, 26th June 2019. The
The Universitat Autònoma de Barcelona (UAB) and Pharmacelera have reached an agreement to perform a research project in the area of Parkinson
Last December, Biocat 1 reported that the Bioregion of Catalonia is witnessing a growth in international investment and described Catalonia as a dynamic
Pharmacelera has been awarded an SME Phase I grant from the European Commission for its MolPredict project. The EU received 2009 requests
The Spanish National Research Centre (CNIO) is a Spanish public institution focused on the research, diagnosis and treatment of cancer. The CNIO
For most of the past decade, the number of drugs approved every year per dollar spent on R&D has remained flat or
Image obtained from Advances in Fragment-Based Drug Discovery by Laura Elizabeth Mason Fragment-Based Drug Design (FBDD) is becoming a useful strategy for
We have been working hard to bring up a new Graphical User Interface (GUI) based on feedback from many computational and medicinal
High-Performance Computing (HPC) has become a priority in Europe and it is called to be a strategic resource for the economic competitiveness [1].
Despite the large number of advances in the scientific and technical field underlying the drug discovery process (DNA sequencing, molecular biology, structural
